Subacute Cutaneous Lupus Erythematosus research hub
4 indexed studies · 2 currently recruiting
- active not recruitingPHASE2
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
This study is testing a new medicine, called IMVT-1402, for people with specific types of lupus that affect the skin. Researchers want to see if it's safe, if people can tolerate it, and if it helps improve skin symptoms compared to a dummy medicine.
United States · Argentina · Bulgaria - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
This study is testing a new medicine, BMS-986326, for people aged 18 and over with lupus, including discoid, subacute cutaneous, or systemic lupus. It aims to see how different doses affect the body and identify common side effects, helping researchers understand if it could be a future treatment.
Netherlands · Poland · Romania - recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
United States · Argentina · Belgium - enrolling by invitationPHASE3
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study looks at the long-term safety and effects of a new drug called litifilimab for adults with certain types of lupus affecting the skin. It's for people who were in an earlier study and whose lupus didn't improve with usual treatments.
United States · Argentina · Brazil